Netherlands' Corbion Q1 revenue falls; starts cost-cut plan and backs FY view

Corbion NV

22/04/2026 06:08

Overview

Netherlands sustainable ingredients firm's Q1 2026 revenue fell 10.9% yr/yr

Adjusted EBITDA for Q1 2026 declined 30.5% yr/yr

Company launched cost reduction program to support full-year margin guidance

Outlook

Corbion affirms FY 2026 guidance on sales growth, adj EBITDA margin, and free cash flow

Company expects Health & Nutrition sales to strengthen from Q2 and offset Q1 weakness

Corbion anticipates return to positive volume/mix growth in remaining 2026 quarters

Result Drivers

HIGH COMPARABLES - Co said Q1 results were affected by a strong prior-year performance in Functional Ingredients & Solutions

NUTRITION BUSINESS PHASING - Co cited expected phasing in the Nutrition business as a factor in lower Q1 sales

LOW OPERATIONAL LEVERAGE - Lower sales in Health & Nutrition led to reduced operational leverage and lower margins

Company press release: ID:nGNE27f23P

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 293.70 mln
Q1 Adjusted EBITDA Margin
12.90%
Q1 Operating Result
EUR 14.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the specialty chemicals peer group is "buy"

Wall Street's median 12-month price target for Corbion NV is €22.50, about 17.8% above its April 21 closing price of €19.10

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)